Compare Regeneron Pharmaceuticals Inc (REGN) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $44.95. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| REGN | USOI | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $812.27 | $61.17 |
52-Week Low | $545.46 | $42.27 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
USOI (Credit Suisse X-Links Crude Oil Shares Covered Call ETN) trades at $46.84 with minimal daily movement (+0.09%). Technical indicators show mixed signals with a bullish moving average trend but bearish oscillators, including overbought RSI readings. The ETN's unique structure as an exchange-traded note tied to oil markets with covered call strategies generates high yields, though financial ratios remain unavailable for this structured product.
The outlook remains tied to oil market volatility and covered call performance, offering high income potential but with significant commodity and counterparty risks. Recent geopolitical tensions have increased oil market volatility, which could impact the ETN's performance and distribution yields.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
